Global CAR T-Cell Therapy Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.

Published Aug 16, 2025

Length 199 Pages

SKU # APRC20359446

Description

Summary

According to APO Research, the global CAR T-Cell Therapy market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for CAR T-Cell Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for CAR T-Cell Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the CAR T-Cell Therapy market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for CAR T-Cell Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the CAR T-Cell Therapy market include J & J, Novartis, Sorrento Therapeutics(Pipeline), Mustang Bio(Pipeline), JW Therapeutics, Gilead Sciences, FOSUNKite, Celyad(Pipeline) and Cellectis(Pipeline), etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for CAR T-Cell Therapy, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of CAR T-Cell Therapy, also provides the value of main regions and countries. Of the upcoming market potential for CAR T-Cell Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CAR T-Cell Therapy revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global CAR T-Cell Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global CAR T-Cell Therapy company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
CAR T-Cell Therapy Segment by Company

J & J
Novartis
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
JW Therapeutics
Gilead Sciences
FOSUNKite
Celyad(Pipeline)
Cellectis(Pipeline)
CARsgen Therapeutics (Pipeline)
Bristol-Myers Squibb
Bluebird Bio(Pipeline)
Autolus Therapeutics(Pipeline)
Allogene Therapeutics(Pipeline)
CAR T-Cell Therapy Segment by Type

CD19 - Targeted
BCMA - Targeted
CAR T-Cell Therapy Segment by Application

Lymphoma
Multiple Myeloma
CAR T-Cell Therapy Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global CAR T-Cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the CAR T-Cell Therapy key companies, revenue, market share, and recent developments.
3. To split the CAR T-Cell Therapy breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions CAR T-Cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify CAR T-Cell Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze CAR T-Cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR T-Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CAR T-Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR T-Cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CAR T-Cell Therapy industry.
Chapter 3: Detailed analysis of CAR T-Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of CAR T-Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of CAR T-Cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

1 Market Overview: 1.1 Product Definition; 1.2 Global CAR T-Cell Therapy Market Size, 2020 VS 2024 VS 2031; 1.3 Global CAR T-Cell Therapy Market Size (2020-2031); 1.4 Assumptions and Limitations; 1.5 Study Goals and Objectives
2 CAR T-Cell Therapy Market Dynamics: 2.1 CAR T-Cell Therapy Industry Trends; 2.2 CAR T-Cell Therapy Industry Drivers; 2.3 CAR T-Cell Therapy Industry Opportunities and Challenges; 2.4 CAR T-Cell Therapy Industry Restraints
3 CAR T-Cell Therapy Market by Company: 3.1 Global CAR T-Cell Therapy Company Revenue Ranking in 2024; 3.2 Global CAR T-Cell Therapy Revenue by Company (2020-2025); 3.3 Global CAR T-Cell Therapy Company Ranking (2023-2025); 3.4 Global CAR T-Cell Therapy Company Manufacturing Base and Headquarters; 3.5 Global CAR T-Cell Therapy Company Product Type and Application; 3.6 Global CAR T-Cell Therapy Company Establishment Date; 3.7 Market Competitive Analysis; 3.7.1 Global CAR T-Cell Therapy Market Concentration Ratio (CR5 and HHI); 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024; 3.7.3 2024 CAR T-Cell Therapy Tier 1, Tier 2, and Tier 3 Companies; 3.8 Mergers and Acquisitions Expansion
4 CAR T-Cell Therapy Market by Type: 4.1 CAR T-Cell Therapy Type Introduction; 4.1.1 CD19 - Targeted; 4.1.2 BCMA - Targeted; 4.2 Global CAR T-Cell Therapy Sales Value by Type; 4.2.1 Global CAR T-Cell Therapy Sales Value by Type (2020 VS 2024 VS 2031); 4.2.2 Global CAR T-Cell Therapy Sales Value by Type (2020-2031); 4.2.3 Global CAR T-Cell Therapy Sales Value Share by Type (2020-2031)
5 CAR T-Cell Therapy Market by Application: 5.1 CAR T-Cell Therapy Application Introduction; 5.1.1 Lymphoma; 5.1.2 Multiple Myeloma; 5.2 Global CAR T-Cell Therapy Sales Value by Application; 5.2.1 Global CAR T-Cell Therapy Sales Value by Application (2020 VS 2024 VS 2031); 5.2.2 Global CAR T-Cell Therapy Sales Value by Application (2020-2031); 5.2.3 Global CAR T-Cell Therapy Sales Value Share by Application (2020-2031)
6 CAR T-Cell Therapy Regional Value Analysis: 6.1 Global CAR T-Cell Therapy Sales Value by Region: 2020 VS 2024 VS 2031; 6.2 Global CAR T-Cell Therapy Sales Value by Region (2020-2031); 6.2.1 Global CAR T-Cell Therapy Sales Value by Region: 2020-2025; 6.2.2 Global CAR T-Cell Therapy Sales Value by Region (2026-2031); 6.3 North America; 6.3.1 North America CAR T-Cell Therapy Sales Value (2020-2031); 6.3.2 North America CAR T-Cell Therapy Sales Value Share by Country, 2024 VS 2031; 6.4 Europe; 6.4.1 Europe CAR T-Cell Therapy Sales Value (2020-2031); 6.4.2 Europe CAR T-Cell Therapy Sales Value Share by Country, 2024 VS 2031; 6.5 Asia-Pacific; 6.5.1 Asia-Pacific CAR T-Cell Therapy Sales Value (2020-2031); 6.5.2 Asia-Pacific CAR T-Cell Therapy Sales Value Share by Country, 2024 VS 2031; 6.6 South America; 6.6.1 South America CAR T-Cell Therapy Sales Value (2020-2031); 6.6.2 South America CAR T-Cell Therapy Sales Value Share by Country, 2024 VS 2031; 6.7 Middle East & Africa; 6.7.1 Middle East & Africa CAR T-Cell Therapy Sales Value (2020-2031); 6.7.2 Middle East & Africa CAR T-Cell Therapy Sales Value Share by Country, 2024 VS 2031
7 CAR T-Cell Therapy Country-level Value Analysis: 7.1 Global CAR T-Cell Therapy Sales Value by Country: 2020 VS 2024 VS 2031; 7.2 Global CAR T-Cell Therapy Sales Value by Country (2020-2031); 7.2.1 Global CAR T-Cell Therapy Sales Value by Country (2020-2025); 7.2.2 Global CAR T-Cell Therapy Sales Value by Country (2026-2031); 7.3 USA; 7.3.1 USA CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.3.2 USA CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.3.3 USA CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.4 Canada; 7.4.1 Canada CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.4.2 Canada CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.4.3 Canada CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.5 Mexico; 7.5.1 Mexico CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.5.2 Mexico CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.5.3 Mexico CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.6 Germany; 7.6.1 Germany CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.6.2 Germany CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.6.3 Germany CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.7 France; 7.7.1 France CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.7.2 France CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.7.3 France CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.8 U.K.; 7.8.1 U.K. CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.8.2 U.K. CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.8.3 U.K. CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.9 Italy; 7.9.1 Italy CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.9.2 Italy CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.9.3 Italy CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.10 Spain; 7.10.1 Spain CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.10.2 Spain CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.10.3 Spain CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.11 Russia; 7.11.1 Russia CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.11.2 Russia CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.11.3 Russia CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.12 Netherlands; 7.12.1 Netherlands CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.12.2 Netherlands CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.12.3 Netherlands CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.13 Nordic Countries; 7.13.1 Nordic Countries CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.13.2 Nordic Countries CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.13.3 Nordic Countries CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.14 China; 7.14.1 China CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.14.2 China CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.14.3 China CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.15 Japan; 7.15.1 Japan CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.15.2 Japan CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.15.3 Japan CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.16 South Korea; 7.16.1 South Korea CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.16.2 South Korea CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.16.3 South Korea CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.17 India; 7.17.1 India CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.17.2 India CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.17.3 India CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.18 Australia; 7.18.1 Australia CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.18.2 Australia CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.18.3 Australia CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.19 Southeast Asia; 7.19.1 Southeast Asia CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.19.2 Southeast Asia CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.19.3 Southeast Asia CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.20 Brazil; 7.20.1 Brazil CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.20.2 Brazil CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.20.3 Brazil CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.21 Argentina; 7.21.1 Argentina CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.21.2 Argentina CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.21.3 Argentina CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.22 Chile; 7.22.1 Chile CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.22.2 Chile CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.22.3 Chile CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.23 Colombia; 7.23.1 Colombia CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.23.2 Colombia CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.23.3 Colombia CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.24 Peru; 7.24.1 Peru CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.24.2 Peru CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.24.3 Peru CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.25 Saudi Arabia; 7.25.1 Saudi Arabia CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.25.2 Saudi Arabia CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.25.3 Saudi Arabia CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.26 Israel; 7.26.1 Israel CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.26.2 Israel CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.26.3 Israel CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.27 UAE; 7.27.1 UAE CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.27.2 UAE CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.27.3 UAE CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.28 Turkey; 7.28.1 Turkey CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.28.2 Turkey CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.28.3 Turkey CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.29 Iran; 7.29.1 Iran CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.29.2 Iran CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.29.3 Iran CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031; 7.30 Egypt; 7.30.1 Egypt CAR T-Cell Therapy Sales Value Growth Rate (2020-2031); 7.30.2 Egypt CAR T-Cell Therapy Sales Value Share by Type, 2024 VS 2031; 7.30.3 Egypt CAR T-Cell Therapy Sales Value Share by Application, 2024 VS 2031
8 Company Profiles: 8.1 J & J; 8.1.1 J & J Comapny Information; 8.1.2 J & J Business Overview; 8.1.3 J & J CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.1.4 J & J CAR T-Cell Therapy Product Portfolio; 8.1.5 J & J Recent Developments; 8.2 Novartis; 8.2.1 Novartis Comapny Information; 8.2.2 Novartis Business Overview; 8.2.3 Novartis CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.2.4 Novartis CAR T-Cell Therapy Product Portfolio; 8.2.5 Novartis Recent Developments; 8.3 Sorrento Therapeutics(Pipeline); 8.3.1 Sorrento Therapeutics(Pipeline) Comapny Information; 8.3.2 Sorrento Therapeutics(Pipeline) Business Overview; 8.3.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.3.4 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio; 8.3.5 Sorrento Therapeutics(Pipeline) Recent Developments; 8.4 Mustang Bio(Pipeline); 8.4.1 Mustang Bio(Pipeline) Comapny Information; 8.4.2 Mustang Bio(Pipeline) Business Overview; 8.4.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.4.4 Mustang Bio(Pipeline) CAR T-Cell Therapy Product Portfolio; 8.4.5 Mustang Bio(Pipeline) Recent Developments; 8.5 JW Therapeutics; 8.5.1 JW Therapeutics Comapny Information; 8.5.2 JW Therapeutics Business Overview; 8.5.3 JW Therapeutics CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.5.4 JW Therapeutics CAR T-Cell Therapy Product Portfolio; 8.5.5 JW Therapeutics Recent Developments; 8.6 Gilead Sciences; 8.6.1 Gilead Sciences Comapny Information; 8.6.2 Gilead Sciences Business Overview; 8.6.3 Gilead Sciences CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.6.4 Gilead Sciences CAR T-Cell Therapy Product Portfolio; 8.6.5 Gilead Sciences Recent Developments; 8.7 FOSUNKite; 8.7.1 FOSUNKite Comapny Information; 8.7.2 FOSUNKite Business Overview; 8.7.3 FOSUNKite CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.7.4 FOSUNKite CAR T-Cell Therapy Product Portfolio; 8.7.5 FOSUNKite Recent Developments; 8.8 Celyad(Pipeline); 8.8.1 Celyad(Pipeline) Comapny Information; 8.8.2 Celyad(Pipeline) Business Overview; 8.8.3 Celyad(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.8.4 Celyad(Pipeline) CAR T-Cell Therapy Product Portfolio; 8.8.5 Celyad(Pipeline) Recent Developments; 8.9 Cellectis(Pipeline); 8.9.1 Cellectis(Pipeline) Comapny Information; 8.9.2 Cellectis(Pipeline) Business Overview; 8.9.3 Cellectis(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.9.4 Cellectis(Pipeline) CAR T-Cell Therapy Product Portfolio; 8.9.5 Cellectis(Pipeline) Recent Developments; 8.10 CARsgen Therapeutics (Pipeline); 8.10.1 CARsgen Therapeutics (Pipeline) Comapny Information; 8.10.2 CARsgen Therapeutics (Pipeline) Business Overview; 8.10.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.10.4 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product Portfolio; 8.10.5 CARsgen Therapeutics (Pipeline) Recent Developments; 8.11 Bristol-Myers Squibb; 8.11.1 Bristol-Myers Squibb Comapny Information; 8.11.2 Bristol-Myers Squibb Business Overview; 8.11.3 Bristol-Myers Squibb CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.11.4 Bristol-Myers Squibb CAR T-Cell Therapy Product Portfolio; 8.11.5 Bristol-Myers Squibb Recent Developments; 8.12 Bluebird Bio(Pipeline); 8.12.1 Bluebird Bio(Pipeline) Comapny Information; 8.12.2 Bluebird Bio(Pipeline) Business Overview; 8.12.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.12.4 Bluebird Bio(Pipeline) CAR T-Cell Therapy Product Portfolio; 8.12.5 Bluebird Bio(Pipeline) Recent Developments; 8.13 Autolus Therapeutics(Pipeline); 8.13.1 Autolus Therapeutics(Pipeline) Comapny Information; 8.13.2 Autolus Therapeutics(Pipeline) Business Overview; 8.13.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.13.4 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio; 8.13.5 Autolus Therapeutics(Pipeline) Recent Developments; 8.14 Allogene Therapeutics(Pipeline); 8.14.1 Allogene Therapeutics(Pipeline) Comapny Information; 8.14.2 Allogene Therapeutics(Pipeline) Business Overview; 8.14.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025); 8.14.4 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio; 8.14.5 Allogene Therapeutics(Pipeline) Recent Developments
9 Concluding Insights
10 Appendix: 10.1 Reasons for Doing This Study; 10.2 Research Methodology; 10.3 Research Process; 10.4 Authors List of This Report; 10.5 Data Source; 10.5.1 Secondary Sources; 10.5.2 Primary Sources

Pricing

Currency Rates

Single User Email from Publisher $4,250
Multi User License Fulfilled by Publisher $6,375
Global Site License Email from Publisher $8,500

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now